- Home
- TGTX vs HGV Comparison
TGTX vs HGV Comparison
Compare TGTX & HGV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TGTX
- HGV
- Stock Information
- Founded
- TGTX 1993
- HGV 1992
- Country
- TGTX United States
- HGV United States
- Employees
- TGTX N/A
- HGV N/A
- Industry
- TGTX Biotechnology: Pharmaceutical Preparations
- HGV Hotels/Resorts
- Sector
- TGTX Health Care
- HGV Consumer Discretionary
- Exchange
- TGTX Nasdaq
- HGV Nasdaq
- Market Cap
- TGTX 4.2B
- HGV 4.0B
- IPO Year
- TGTX 1995
- HGV N/A
- Fundamental
- Price
- TGTX $33.09
- HGV $45.44
- Analyst Decision
- TGTX Strong Buy
- HGV Buy
- Analyst Count
- TGTX 4
- HGV 7
- Target Price
- TGTX $42.50
- HGV $51.29
- AVG Volume (30 Days)
- TGTX 2.0M
- HGV 908.4K
- Earning Date
- TGTX 11-03-2025
- HGV 11-06-2025
- Dividend Yield
- TGTX N/A
- HGV N/A
- EPS Growth
- TGTX N/A
- HGV N/A
- EPS
- TGTX 0.36
- HGV 0.57
- Revenue
- TGTX $454,069,000.00
- HGV $4,478,000,000.00
- Revenue This Year
- TGTX $82.58
- HGV $15.79
- Revenue Next Year
- TGTX $44.99
- HGV $8.63
- P/E Ratio
- TGTX $88.20
- HGV $79.43
- Revenue Growth
- TGTX 30.96
- HGV 12.43
- 52 Week Low
- TGTX $21.16
- HGV $30.59
- 52 Week High
- TGTX $46.48
- HGV $52.08
- Technical
- Relative Strength Index (RSI)
- TGTX 54.72
- HGV 52.99
- Support Level
- TGTX $31.34
- HGV $45.14
- Resistance Level
- TGTX $32.56
- HGV $47.76
- Average True Range (ATR)
- TGTX 1.03
- HGV 0.90
- MACD
- TGTX -1.33
- HGV -2.66
- Stochastic Oscillator
- TGTX 99.06
- HGV 93.29
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.
About HGV Hilton Grand Vacations Inc.
Hilton Grand Vacations Inc is a timeshare company engaged in developing, marketing, selling, managing, and operating timeshare resorts, timeshare plans, and ancillary reservation services, under the Hilton Grand Vacations brand. The company operates business in the following two segments: (i) Real estate sales and financing and (ii) Resort operations and club management. The majority of the company's revenue is earned through the Real estate sales and financing segment, which generates revenue from VOI sales, and Financing.